Skip to main content
SMS Pharmaceuticals Ltd logo

SMS Pharmaceuticals Ltd — Investor Relations & Filings

Ticker · SMSPHARMA ISIN · INE812G01025 LEI · 335800XXEADQCB7GJ514 BSE.NS Manufacturing
Open in API
Filings indexed 747 across all filing types
Latest filing 2026-05-25 Regulatory Filings
Country IN India
Listing BSE.NS SMSPHARMA

About SMS Pharmaceuticals Ltd

https://smspharma.com/

SMS Pharmaceuticals Ltd specializes in the development and large-scale manufacturing of Active Pharmaceutical Ingredients (APIs) and advanced intermediates. The organization operates multiple manufacturing units and research centers, maintaining compliance with international regulatory standards including USFDA approvals. Its core product portfolio covers therapeutic areas such as anti-ulcerants, anti-migraine agents, anti-hypertensives, and anti-retrovirals. Beyond its proprietary product line, the company provides Contract Research and Manufacturing Services (CRAMS), offering expertise in process development, chemical synthesis, and analytical validation. The company focuses on delivering high-quality chemical solutions through integrated research and development capabilities, supporting global supply chains with a commitment to technical excellence and operational efficiency.

Recent filings

Filing Released Lang Actions
Copy of Newspaper Publication
Regulatory Filings Classification · 80% confidence The document is a mandatory intimation sent to BSE and NSE under Regulation 47 read with Regulation 33 enclosing newspaper advertisements of the audited standalone and consolidated financial results for Q4 and year ended March 31, 2026. It is not the full annual or interim report itself but a compliance filing of newspaper cuttings, with no substantive MD&A or investor presentation. This falls under general regulatory announcements/compliance documents, making it a Regulatory Filing (RNS).
2026-05-25 English
copy of newspaper publication
Report Publication Announcement Classification · 85% confidence The document is a formal letter dated 25 May 2026 from SMS Pharmaceuticals to the stock exchanges, enclosing newspaper cuttings of the audited standalone and consolidated financial results for Q4 and FY ended 31 March 2026. It does not itself present a full annual or quarterly report with MD&A, but simply announces and attaches published ads. Under the “menu vs meal” rule, this is an announcement of report publication rather than the report itself. Therefore it should be classified as a Report Publication Announcement (RPA).
2026-05-25 English
General Updates
Investor Presentation Classification · 95% confidence The document is an investor presentation slide deck provided under Regulation 30, including Safe Harbour slides, financial highlights (Q4 & FY26), company overview, strategy, and historical P&L tables. This matches the definition for an Investor Presentation (Code: IP).
2026-05-23 English
Investor Presentation
Investor Presentation Classification · 95% confidence The document is a detailed slide deck titled “Investor Presentation” sent to stock exchanges under SEBI Listing Obligations for the quarter and year ended March 31, 2026. It contains financial highlights, strategy, performance review, and forward-looking statements typical of an investor presentation rather than an annual report or earnings release. Hence, it should be classified as an Investor Presentation.
2026-05-23 English
Press Release on Financial Results for the year ended 31.03.2026
Earnings Release Classification · 90% confidence The document is a press release submitted to stock exchanges announcing the audited financial results for the quarter and full year ended March 31, 2026. It provides key financial highlights (PAT, EBITDA margins, revenue growth), a summary table of results by period, and management commentary—characteristic of an earnings release. It is not a full annual or interim report, nor a regulatory filing announcement or certification. Therefore, it matches the definition of an Earnings Release (ER). FY 2026
2026-05-23 English
Press Release
Earnings Release Classification · 93% confidence The document is a corporate press release announcing audited financial results for the quarter and full year ended March 31, 2026. It provides key performance highlights (revenue, EBITDA, PAT, margins), segmental tables, management commentary, outlook, and dividend declaration. This aligns with an Earnings Release (initial announcement of periodical financial results), not a full annual or interim report filing. FY 2026
2026-05-23 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.